Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unraveling the Epigenetic Landscape of Sarcopenic Obesity: Insights into DNA Methylation Mechanisms from a Pilot Study in Older Women

ABSTRACT: Epigenetic alterations, particularly DNA methylation, are recognized as robust biomarkers of ageing and have been associated with conditions such as obesity and sarcopenia. When these two conditions coexist, the result is sarcopenic obesity (SO), a functional and clinical condition characterized by excess fat mass and reduced muscle mass and function. Although cross-talk between muscle and fat tissue is thought to play a central role in SO pathophysiology, the epigenetic mechanisms involved remain poorly understood. Thus, this study aimed to investigate whole-blood DNA methylation patterns in older women with sarcopenic obesity, obesity, sarcopenia, and normal weight, as well as to explore the associated signaling pathways.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303899 | GEO | 2026/03/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Changes in Pdgfra-positive mesenchymal progenitors during muscle regeneration under normal and obese condition.

Project description:Worldwide increases in obese and elderly populations synergistically enhance the incidence of sarcopenia. Accumulation of intermuscular adipose tissue (IMAT) is considered to be a major problem whereby obesity leads to sarcopenic obesity and thus is a promising target for treating this emerging pathological condition. However, while sarcopenic obesity-associated IMAT is suggested to be originated from PDGFRα+ mesenchymal progenitors, processes of their adipogenesis remain largely unexplored. Here we investigated intracellular changes associated with these processes using scRNA-Seq analysis.

2021-01-15 | E-MTAB-9715 | biostudies-arrayexpress

Single-nuclei profiling of aged skeletal muscle

Project description:Aging is accompanied by a loss of muscle mass and function, termed sarcopenia, causing numerous morbidities and economic burdens in human populations. Mechanisms implicated in age-related sarcopenia include inflammation, muscle stem cell depletion, mitochondrial dysfunction and loss of motor neurons, but whether there are key drivers of sarcopenia is not yet known. To gain deeper insights into age-related sarcopenia, we performed transcriptome profiling on lower limb muscle biopsies from 72 young, old and sarcopenic subjects using bulk RNA-seq (N = 72) and single-nuclei RNA-seq (N = 17). Using this combined approach, we discovered novel changes in gene expression that occur with age and sarcopenia in multiple cell types comprising mature skeletal muscle. Notably, we found increased expression of the genes MYH8 and PDK4, and decreased expression of the gene IGFN1, in old muscle. We also identified a small population of nuclei that express CDKN1A, present only in aged samples, consistent with P21CIP1 senescence in this subpopulation. Our findings identify unique cellular sub-populations populations in aged and sarcopenic skeletal muscle, which will facilitate the development of new therapeutic strategies to combat age-related sarcopenia.

2022-03-31 | GSE167186 | GEO

Transcriptomic analysis of sarcopenic obese mice reveals alterations in regulators of muscle force production, such as extracellular matrix remodeling and shifts in muscle fiber type

Project description:Sarcopenic obesity (SO) is the combined condition of sarcopenia and obesity most commonly occurring in the older adult population. SO is associated with poor physical function, increased risk of musculoskeletal injury, and reduced quality of life and independence. There is little information on the molecular underpinnings of this condition. The aim of this study was to provide a transcriptomic analysis characterizing SO and to provide deeper understanding to the etiology of the condition. Young (Y) (6 mo) and aged (A) (21-24 mo) mice were fed either normal chow (L) (12% kcal from fat) or high-fat (O) (60% kcal from fat) diets ad libitum. Through multiple analyses, we observed genes related to ECM remodeling are downregulated with aged-obesity compared with young obesity, providing insight to the effects of age in a life-long obese condition. Furthermore, genes related to slow-twitch muscle contraction and fast-to-slow muscle fiber type transitions were upregulated in with obesity in the aged condition. Together, our results demonstrate avenues of dysregulation in SO skeletal muscle, providing the molecular building blocks expanding our understanding of the etiology of poor muscle function in this condition. Further understanding and exploration of these dysregulations is critical to identify therapeutic treatments targeting the source of muscle functional impairment, reducing the risk of musculoskeletal injury, and improving quality of life and independence SO individuals.

2025-08-05 | GSE290570 | GEO

Luteolin protects against obese sarcopenia in mice with high-fat diet-induced obesity by ameliorating inflammation and protein degradation in muscle

Project description:Although there are studies on obesity and sarcopenia, our understanding of obesity-mediated sarcopenia is insufficient. Additionally, no studies have investigated the application of luteolin in sarcopenia. We attempted to determine the effect of luteolin on obese sarcopenia in mice with high-fat diet (HFD)-induced obesity. Luteolin exerted suppressive effects on obesity, inflammation, and protein degradation in HFD-fed obese mice. Luteolin inhibited lipid infiltration into the muscle and decreased p38 and JNK activity and mRNA expression of inflammatory factors, such as TNFα, Tlr2, Tlr4, MCP1, and MMP2, in the muscle. Suppression of muscle inflammation by luteolin led to the inhibition of myostatin, FoxO, atrogin, and MuRF expression, which reduced protein degradation and improved muscle function. This is the first study to demonstrate that luteolin exerts a protective effect against obese sarcopenia, as its anti-obesity and anti-inflammatory activities inhibited protein degradation. Therefore, luteolin may be a useful supplement for prevention of obese sarcopenia.

2022-07-27 | GSE209778 | GEO

The serum small non-coding RNA (SncRNA) landscape as a molecular biomarker of age associated muscle dysregulation and insulin resistance in older adults.

Project description:Small noncoding RNAs (sncRNAs) are implicated in age-associated pathologies, including sarcopenia and insulin resistance (IR). This study aimed to characterise the wider circulating sncRNA transcriptome of older individuals and associations with sarcopenia and IR. Total RNA was used for sncRNA expression including miRNAs, transfer RNAs (tRNAs), tRNA-associated fragments (tRFs) and piwi-interacting RNAs (piRNAs) was measured in serum from 21 healthy and 21 sarcopenic women matched for age (mean 78.9 years) and HOMA2-IR from the Hertfordshire Sarcopenia Study. Associations with age, sarcopenia and HOMA2-IR were examined, and predicted gene targets and biological pathways characterised.

2024-03-27 | GSE231785 | GEO

Study of sarcopenia in human muscle biopsies of elderly individuals, Singapore Sarcopenia Study

Project description:Purpose: The main goal of this study is to compare skeletal muscle transcriptome profilings derived from sarcopenic versus healthy subjects. Methods: We use high coverage RNA sequencing of human skeletal muscle biopsies to analyze genome-wide transcriptional changes in human sarcopenia benchmarked to healthy elderly controls. Results: Muscle transcriptomic profiles demonstrate a prominent signature of mitochondrial dysfunction in sarcopenic patients. Conclusions: Our study supports the fundamental role of mitochondrial dysfunction in driving pathological muscle and mobility decline in the elderly.

2019-11-14 | GSE111016 | GEO

Study of sarcopenia in human muscle biopsies of elderly individuals, Hertfordshire Sarcopenia Study

2019-11-14 | GSE111006 | GEO

Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans

Project description:The new generation of incretin-based therapies are potent anti-obesity medications (AOMs) that offer the first non-surgical treatment for 936 million patients globally suffering from being overweight or obese (Federation, 2025). However, clinical data suggest that incretin-mimetics could cause a disproportionate decrease in lean body mass (LBM) (Jastreboff et al., 2022; Wilding et al., 2021), raising a concern for deterioration of skeletal muscle and acceleration of sarcopenic obesity (Prado et al., 2024). Unfortunately, muscle mass and function are not routinely assessed in obesity studies and original data on the matter remains sparse. In this work, we conducted various pre-clinical studies and a proof-of-concept clinical trial to examine how skeletal muscle is affected by AOMs. The overarching goal of our studies were to test if AOMs affect muscle mass disproportionately or whether changes are a simple function of weight loss. We found that in mice with diet-induced obesity (DIO), incretin-based therapies result predominantly in a substantial decrease in fat mass alongside a small but significant decrease in LBM. Among the lean tissues, the decrease in liver mass exceeded the change in muscle mass robustly. While absolute muscle mass did decrease, relative muscle mass (i.e., the muscle mass to body weight (BW) ratio) improved significantly. Similarly, we found that absolute muscle strength decreased mildly but increased relative to the BW of mice.

2026-01-22 | PXD070915 | Pride

miRNA expression data from sedentary and exercised rats

Project description:Loss of skeletal muscle mass during aging, also known as sarcopenia, is a worldwide health problem. The etiology of sarcopenia remains unknown; however, recent studies revealed that sedentarism, fat gain, and epigenetic regulators such as miRNAs are critical regulators in its developing. One effective intervention to prevent and treat sarcopenia is aerobic exercise. We used miRNA microarrays to determine the changes in miRNA expression through time and the differences between sedentary and lifelong exercised rats.

2021-05-24 | GSE175390 | GEO

Unraveling the Epigenetic Landscape of Sarcopenic Obesity: Insights into DNA Methylation Mechanisms from a Pilot Study in Older Women

Project description:Unraveling the Epigenetic Landscape of Sarcopenic Obesity: Insights into DNA Methylation Mechanisms from a Pilot Study in Older Women

| PRJNA1298191 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data